A Peptide-Based Vaccine to Nicotine

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$99,510.00
Award Year:
2004
Program:
STTR
Phase:
Phase I
Contract:
1R41DA016843-01
Award Id:
71443
Agency Tracking Number:
DA016843
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
PROMMUNE LLC, 4625 S 154TH CIR, OMAHA, NE, 68137
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
SAMSANDERSON
(402) 559-5353
SDSANDER@UNMC.EDU
Business Contact:
DEBORAHVETTER
() -
SPADMIN@UNMC.EDU
Research Institute:
UNIVERSITY OF NEBRASKA LINCOLN

312 N. 14TH STREET
OMAHA, NE, 68588

Nonprofit college or university
Abstract
DESCRIPTION (provided by applicant): The primary objective of this Phase I STTR project is to develop an effective, peptide-based nicotine vaccine for use in humans capable of inducing a robust, nicotine-specific antibody (Ab) response with little or no inflammatory side effects. This will be accomplished by a vaccine design in which a conformationally biased, response-selective agonist Of C5a (YSFKPMPLaR) is used as a molecular adjuvant, a nicotine hapten is used as the target antigen (Ag), and a nonhuman B cell epitope is used to assist hapten processing by antigen presenting cells (APC). The ability of such vaccines to induce anti-nicotine responses will be assessed by vaccinating rats in the absence of added adjuvant and demonstrating: 1) the presence of nicotine-specific Abs in immune sera and 2) an attenuation of nicotine-induced psychoactive effects in two well-established rat models of nicotine dependence - locomotor activity and drug appetitive conditioning. Validation of this peptide-based nicotine vaccine represents the first step toward realization of the broad, commercial objective sought by this project, which is to use vaccination to nicotine with such vaccines as a standard therapeutic regimen for smoking cessation and maintenance of long term compliance. As has been shown in rats, the therapeutic effect in humans will result from the ability of Abs generated in response to the vaccine to bind circulating nicotine with high affinity/selectivity, thereby decreasing nicotine distribution to the brain where it exerts its addictive effects. The central design feature of this nicotine vaccine design is YSFKPMPLaR, which has been shown to be n effective molecular adjuvant in the induction of Ab responses to peptide and non-peptide Ags. Thus, it is hypothesized that an effective YSFKPMPLaR-containing nicotine vaccine can be developed for human use when a nonhuman B cell epitope is used for assistance in nicotine hapten processing and presentation. This hypothesis will be evaluated by the following specific aims: 1) To test YSFKPMPLaR-containing nicotine vaccines, which utilize nonhuman epitopes to assist hapten processing and presentation, for their ability to produce anti-nicotine Abs in rats immunized in the absence of added adjuvants, and 2) To evaluate the effectiveness of vaccination with the vaccine(s) from Aim 1 in attenuating nicotine-induced behavioral effects in two well-characterized rat models of nicotine dependence. A nicotine vaccine that satisfies these aims would be a candidate vaccine for human clinical trials in Treating nicotine dependence via vaccination as an approach for smoking cessation.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government